Study Says Combined Drugs Can Shrink Tumour By 60 Percent In Bowel Cancer

Updated Jul 25, 2024 | 06:09 PM IST

SummaryA new study has found that combining the use of botanciiimab and balstilumab can reduce tumours caused by bowel cancer by 60%, marking the first time a durable response to immunotherapy has been reported in patients suffering from this condition.
close-up-medicine-containers-table

A new study has found that a combination of two drugs could enhance the immune system to treat one of the most common types of cancer in the world, bowel cancer. Also known as colorectal cancer, despite its widespread presence, the treatment options for this condition are limited. What the study specifically found was that this procedure could shrink the tumours caused by this condition by around 60%.

What Are The Drugs Involved

The trial involved the use of two immunotherapy drugs, botancilimab and balstilumab. It is a monoclonal antibody that works to stimulate the body's immune system to attack cancer. The study is a rather significant find, as it’s the first time that a consistent and durable response to immunotherapy has been reported in patients with solid MSS mCRC tumours.

The study was divided into several phases for more than 6 months. In the US trial, around around 101 patients with microsatile stable metastatic colorectal (MSS-mCRC) tumours showed a decrease . Around 61% of the patients experienced tumour shrinkage or stabilization after combined treatment with votancilumab and balstilumab. When it comes to downsides, diarrhea and fatigue were found to be the most common side effects or side effects of this drug.

These results are interesting and open to exploration. To date, immunotherapy has not been effective in patients with CNS-mCRC tumors. This study demonstrates the potential of the combination of botenlimab and balstilimab in the treatment of CNS mCRC, providing new hope for people diagnosed with colon cancer.

What Could This Mean For Bowel Cancer Treatment In The Future

The study is currently in the final stages of clinical trials, and the US Food and Drug Administration (FDA) hopes to quickly gain approval for its use because of the importance of this area that affects many people. The efficiency shown demonstrates the potential of botansilimab to contribute to broad antitumor immunity.

All in all, the combination of botensilimab and balstilimab represents a promising new direction in the treatment of colorectal cancer. This breakthrough could improve conditions for many patients worldwide and lights a new hope in the fight against this common disease. The results of this study show the effectiveness of immunotherapy in this field and how its potential to transform cancer treatment can only grow in the years to come.

End of Article

Trials For Deadly Childhood Brain Cancer Stalled After Trump Administration Shuts Down 27-Year Research Consortium

Updated Nov 17, 2026 | 06:00 PM IST

SummaryPediatric Brain Tumor Consortium (PBTC)'s shutdown has impacted multiple clinical trials and research of aggressive childhood brain cancer like diffuse intrinsic pontine glioma (DIPG) and ependymoma.
Trials For Deadly Childhood Brain Cancer Stalled After Trump Administration Shuts Down 27-Year Research Consortium

Credit: AI-generated image

Clinical trials investigating experimental treatments for rare, aggressive childhood brain cancers have been disrupted after the closure of a US research consortium that was in operation for 27 years.

The shutdown of the Pediatric Brain Tumor Consortium (PBTC), after the National Cancer Institute (NCI) declined to renew its funding, has caused significant delays and rendered desperate families searching for alternative treatment options.

The consortium was composed of 16 leading children's hospitals and academic medical centres across the US, aiming to investigate new treatments for aggressive brain tumours, including diffuse intrinsic pontine glioma (DIPG) and ependymoma.

The NCI informed consortium leaders about the decision in August 2025, ending its approximately $4 million annual grant. Eight ongoing clinical trials were subsequently halted, according to The New York Times.

The consortium formally dissolved in September 2026. Researchers say the disruption has affected not only ongoing studies but also the infrastructure and resources needed to develop new treatments for childhood brain cancers.

DIPG Is One Of The Most Aggressive Childhood Brain Cancers

Also read: Losing Balance While Walking? Doctors Explain When It Could Be A Neurological Warning Sign

DIPG is a rare, aggressive brain tumour that usually affects children between four and 10 years of age. It develops in the pons, a part of the brainstem which is responsible for essential functions like breathing, heart rate, coordination and balance.

Since the tumour grows within critical brain tissue and spreads through the brainstem, it cannot be removed through surgery. Clinicians describe it “like sand in grass”.

Radiation therapy is commonly used to fight the tumour but its benefits are temporary. There is currently no established treatment. The average survival after diagnosis is approximately nine to 12 months.

With limited treatment options, clinical trials investigating experimental therapies are a need of the hour for children suffering from DIPG.

Research And Clinical Trials That Were Affected Due To Funding Closure

Also read: AIIMS Delhi Performs India's First Open Fetal Surgery To Repair Spina Bifida

The closure disrupted several studies exploring experimental treatments for childhood brain tumours.

One of the affected studies, PBTC-059, was a Phase 1 trial investigating CAR-T cell therapy in children with ependymoma. CAR-T therapy entails modifying a patient's immune cells to identify and attack cancer cells.

Another study, PBTC-N14, was discontinued too. Researchers at Memorial Sloan Kettering Cancer Center were investigating whether cerebrospinal fluid samples could provide genetic information similar to that obtained through an invasive brain biopsy, reducing the need for surgery in some children.

Researchers were also exploring other experimental options for DIPG, including cancer vaccines and devices that can deliver electrical stimulation to the brain.

According to the NCI's updated information, some paused trials are expected to reopen to patient enrolment in late 2026 or early 2027. But the interruption has created a significant gap and delay for families who were previously able to access these trials.

27 Years Of Research Data At Stake

Also read: Beth Dobbin's Myalgic Encephalomyelitis Campaign Gains Support From 360 Sportspeople: Why Are They Urging UK PM To Act?

The consequences of the consortium's closure extend well beyond clinical trial enrolment and patient welfare. At St. Jude Children's Research Hospital, 27 years of research data involving more than 2,000 children with rare brain tumours had to be archived.

Hundreds of biological samples, including tumour tissue, blood and spinal fluid collected from patients, also had to be returned to hospitals or destroyed if they could not be retained.

Researchers have raised concerns that losing the consortium's dedicated infrastructure and centralised data-access system could make it harder for scientists to resume these studies and build on previous findings.

Ira Dunkel, a paediatric oncologist at Memorial Sloan Kettering Cancer Center and former chair of the consortium, described the closure as “catastrophic” and one of the worst professional moments of his career.

Why Did The US Government Shut Down PBTC?

The NCI said the decision was taken to improve efficiency by moving the consortium's data into the larger Pediatric Early Phase Clinical Trials Network. The institute also said enrolment in some consortium studies had slowed.

But researchers argued that the smaller patient populations and the highly targeted nature of experimental treatments make specialised research areas particularly important.

After the decision, NCI announced that approximately $4 million would be allocated to the larger network to strengthen paediatric brain tumour research and accelerate Phase 1 clinical trials.

The $4 million grant also seemed insufficient compared to the $732 million that the NIH spends annually on childhood cancer. But according to Dunkel, it was “hugely important”.

But researchers and patient support groups have questioned whether the larger network can immediately and effectively replace the consortium's specialised expertise, proven collaborations and research infrastructure.

A bipartisan group of lawmakers from New York called wrote to Health and Human Services Secretary Robert F. Kennedy Jr., urging to reverse the decision. “We cannot afford to take this step backward,” the group said.

Families dealing with aggressive childhood brain cancers are helpless in the light of consortium closure. With some children having less than a year after diagnosis, such setbacks mean losing access to potentially life-saving or extending experimental treatment opportunities that may not become available again in time.

End of Article

India Moves Into The Trajectory Of Developed World, Doubles Social Security Expenditure In A Decade

Updated Nov 17, 2026 | 04:15 PM IST

SummaryThe National Health Accounts (NHA) Estimates for India 2023–24 revealed that government health expenditure more than tripled over the past decade, rising from ₹1,29,778 crore in 2013–14 to ₹4,14,196 crore in 2023–24.
India Moves Into The Trajectory Of Developed World, Doubles Social Security Expenditure In A Decade

Credit: AI Image

India’s social security expenditure on health nearly doubled as a share of Total Health Expenditure, rising from 6% in 2013–14 to 11% in 2023–24, according to the Union Health Ministry. The spending, estimated to have crossed Rs 1 lakh crore, aims to protect individuals and families against the financial risks associated with medical treatment.

This growth has been led by whopping contributions of the government's flagship health insurance schemes such as Ayushman Bharat – Pradhan Mantri Jan Arogya Yojana (AB PM-JAY), state-specific health insurance schemes, social health insurance and medical expenditure for government employees.

Private health insurance expenditure also increased, rising from 3.4% of Total Health Expenditure in 2013-14 to 10.2% in 2023-24.

Government Health Expenditure Triples In A Decade

Also read: Ayushman Bharat Turns 8: PM Modi Highlights Record Savings On Medical Expenses

According to the National Health Accounts (NHA) Estimates for India 2023-24, released by the Ministry of Health and Family Welfare, India’s government health expenditure nearly tripled over the past decade, increasing from Rs 1,29,778 crore in 2013-14 to Rs 4,14,196 crore in 2023-24.

The government’s share of Total Health Expenditure (THE) increased by 14.9 percentage points over the decade, representing a rise of nearly 52%.

The report also highlighted an increase in per-capita government health expenditure and a decline in households’ out-of-pocket spending on healthcare.

“A healthier India. Lower financial burden. Stronger healthcare for all!” Union Health Minister JP Nadda said in a post on X while sharing the data.

"The National Health Accounts 2023–24 tell a powerful story of India’s healthcare transformation over the last decade," he added.

India Moves Into The Trajectory Of Developed World, Doubles Social Security Expenditure In A Decade

Per-Capita Government Health Spending Rises 184% In A Decade

Per-capita government health expenditure increased by 184% over the decade, nearly tripling from Rs 1,042 in 2013-14 to Rs 2,959 in 2023-24.

Spending crossed Rs 2,000 in 2019-20, reaching Rs 2,014, and rose further to Rs 2,328 in 2020-21.

The highest per-capita expenditure was recorded in 2021-22 at Rs 3,169, driven by emergency COVID-19 spending. It subsequently declined by 12.1% to Rs 2,786 in 2022-23 before increasing by 6.2% to Rs 2,959 in 2023-24.

The year-on-year growth rate peaked at 36.1% in 2021-22. Among the years that recorded an increase, the lowest growth was 6.2% in 2023-24.

“These are not just numbers. They reflect a decade of sustained efforts to make quality healthcare more affordable,” Nadda said.

He attributed the progress to initiatives such as Ayushman Bharat and Ayushman Arogya Mandirs under Prime Minister Narendra Modi. He also highlighted expanded access to free medicines and diagnostics as part of efforts to strengthen healthcare delivery.

"Our commitment is simple: No family should have to choose between its health and its financial well-being. A Swasth Bharat is the foundation of a Viksit Bharat!" Nadda said.

Public Investment In Primary Healthcare Triples

Public investment in primary healthcare also nearly tripled over the decade, rising from Rs 50,010 crore in 2013-14 to Rs 1,52,771 crore in 2023-24, according to the NHA estimates.

Out-Of-Pocket Health Expenditure Falls

Read More: India Digitalizes Health Records Of 100 Crore People Under Ayushman Bharat

The share of out-of-pocket expenditure (OOPE) in Total Health Expenditure declined from 64.2% in 2013-14 to 42.7% in 2023-24, a drop of 21.5 percentage points.

This indicates that households are paying a smaller share of overall healthcare costs directly, while other financing sources, including government spending and health insurance, account for a larger share.

Government Initiatives Expanding Access To Affordable Healthcare

The Ministry also highlighted several initiatives aimed at improving access to affordable healthcare across the country. These include:

  • Free Drugs and Diagnostics Initiatives
  • Pradhan Mantri National Dialysis Programme
  • Pradhan Mantri Bhartiya Janaushadhi Pariyojana
  • Affordable Medicines and Reliable Implants for Treatment (AMRIT) pharmacies.

End of Article

'Viagra For The Brain': New Pill Slows Decline in Memory, Thinking By 31% In Some Alzheimer's Patients

Updated Nov 17, 2026 | 11:08 AM IST

SummaryDeveloped by South Korean pharmaceutical company AriBio, the drug, AR1001 (mirodenafil), slowed disease progression including memory, thinking, and everyday functioning by the equivalent of 3.5 months over one year.
'Viagra For The Brain': New Pill Slows Decline in Memory, Thinking By 31% In Some Alzheimer's Patients

Credit: iStock

A new once-daily experimental pill slowed the decline in memory, thinking, and everyday functioning by 31% in some people with Alzheimer's disease in a Phase 3 trial.

Developed by South Korean pharmaceutical company AriBio, the drug, AR1001 (mirodenafil), slowed disease progression by the equivalent of 3.5 months over one year.

Unlike existing dementia drugs, which primarily alleviate symptoms, AR1001 has shown potential to slow disease progression.

However, the benefit was significant only among patients who were not taking other dementia medications.

The company announced that "the trial had met its primary endpoint" at the Clinical Trials on Alzheimer's Disease (CTAD) conference in Boston, US.

What Did The Phase 3 Trial Find?

Also read: Normal Ageing or Alzheimer's? Doctors Explain Six Key Differences to Watch For

The global trial involved 1,535 people with Alzheimer's disease across 230 sites in 13 countries.

Researchers assessed participants using the Clinical Dementia Rating–Sum of Boxes (CDR-SB), which measures memory, judgment and the ability to perform everyday activities.

The findings showed:

  • 31% slower decline: Among 604 patients taking AR1001 without other dementia medications, disease progression was 31% slower than in the placebo group.
  • 3.5-month delay: The difference was equivalent to delaying disease progression by approximately 3.5 months over one year.
  • No significant benefit in the overall group: Among all 1,535 participants, the benefit was 7% and was not statistically significant.

The findings suggest that AR1001's effectiveness may depend on whether patients are taking other Alzheimer's medications.

Dr Richard Oakley, Associate Director for Research and Innovation at Alzheimer's Society, described the results as encouraging.

"These topline results are an encouraging sign that we could have a new treatment for early Alzheimer's disease that tackles its causes, not just its symptoms," Dr Richard said, the Daily Mail reported.

"Over the year of the trial, the drug was able to slow down people's decline in memory and thinking by nearly a third," he added.

Why Is AR1001 Being Called 'Viagra For The Brain'?

Read More: India Gets Its First Alzheimer’s Drug: Know All About Eli Lilly’s Lormalzi

AR1001 works differently from existing Alzheimer's treatments, such as lecanemab and donanemab, which target amyloid plaques in the brain.

Its active ingredient, mirodenafil, belongs to the same class of drugs as sildenafil, the compound used in Viagra to treat erectile dysfunction.

Both drugs inhibit an enzyme called phosphodiesterase-5 (PDE5). This helps relax blood vessels and improve blood flow.

Researchers believe AR1001 may have several effects in the brain, including:

  • Improving blood flow.
  • Reducing inflammation.
  • Protecting nerve cells.
  • Supporting cellular processes involved in brain function.

Unlike some existing disease-modifying treatments that require infusions or injections, AR1001 is designed as a once-daily oral medication.

However, the drug is from the same family of medicines as Viagra and is being developed specifically for Alzheimer's disease. People should not take Viagra to try to treat Alzheimer's.

Are there Any Side Effects?

Most side effects reported during the trial were mild to moderate. Common side effects included diarrhoea, falls and dizziness.

Severe adverse events occurred in 10% of the treatment group and 9.8% of the placebo group.

Researchers also reported changes in biomarkers associated with Alzheimer's disease. Levels of the protein p-tau217 decreased in the monotherapy group, while cerebrospinal fluid cGMP levels increased in both treatment groups.

These findings offer clues about the drug's biological activity, although further research is needed to establish its effects.

However, the lack of a statistically significant benefit among people taking other Alzheimer's medications, adding that this required further investigation.

AR1001 is not yet available to the public and must undergo regulatory assessment before it can be prescribed.

Regulatory approval will depend on further evaluation, including whether the FDA considers the monotherapy results sufficient to support the drug's approval.

End of Article